Abstract
Neratinib (NERLYNX®) is indicated for the extended adjuvant treatment of adult patients with early-stage HR+/HER2-overexpressed/amplified breast cancer, who completed adjuvant trastuzumab-based therapy <1 year ago. This infographic offers valuable guidance to nurses in effectively managing neratinib patients to ensure they reap the maximum advantages from this therapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
